Xie et al. [30] found that tumor-specific SPP1+ macrophages drive the evolution of intratumor heterogeneous structures with tumor progression and that SPP1 can be used as a prognostic marker for patients with advanced GC and a potential therapeutic target for GC. The gene discussed is SPP1; the disease is neoplasm.